<code id='84E6DFEDD3'></code><style id='84E6DFEDD3'></style>
    • <acronym id='84E6DFEDD3'></acronym>
      <center id='84E6DFEDD3'><center id='84E6DFEDD3'><tfoot id='84E6DFEDD3'></tfoot></center><abbr id='84E6DFEDD3'><dir id='84E6DFEDD3'><tfoot id='84E6DFEDD3'></tfoot><noframes id='84E6DFEDD3'>

    • <optgroup id='84E6DFEDD3'><strike id='84E6DFEDD3'><sup id='84E6DFEDD3'></sup></strike><code id='84E6DFEDD3'></code></optgroup>
        1. <b id='84E6DFEDD3'><label id='84E6DFEDD3'><select id='84E6DFEDD3'><dt id='84E6DFEDD3'><span id='84E6DFEDD3'></span></dt></select></label></b><u id='84E6DFEDD3'></u>
          <i id='84E6DFEDD3'><strike id='84E6DFEDD3'><tt id='84E6DFEDD3'><pre id='84E6DFEDD3'></pre></tt></strike></i>

          comprehensive

          comprehensive

          author:comprehensive    Page View:59
          Marian F. Moratinos for STAT

          Enticed by the immense market opened by GLP-1 weight loss drugs Wegovy and Zepbound, a handful of biotech companies are trying to develop next-generation, longer-lasting therapies based on a very different approach: RNA interference.

          This Nobel Prize-winning science works by degrading the biological blueprints that RNA use to make proteins — without the genetic instructions, the troublesome proteins are never made and the gene is essentially muted.

          advertisement

          If the companies succeed, it would be a significant shift in the obesity treatment revolution, away from weekly drugs targeting hormones to medications that could be given much less frequently — twice a year or even less — and pinpoint genetic contributors to weight.

          STAT+ Exclusive Story

          Already have an account? Log in

          STAT+

          This article is exclusive to STAT+ subscribers

          Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

          Already have an account? Log in

          Already have an account? Log in

          Monthly

          $39

          Totals $468 per year

          $39/month Get Started

          Totals $468 per year

          Starter

          $30

          for 3 months, then $39/month

          $30 for 3 months Get Started

          Then $39/month

          Annual

          $399

          Save 15%

          $399/year Get Started

          Save 15%

          11+ Users

          Custom

          Savings start at 25%!

          Request A Quote Request A Quote

          Savings start at 25%!

          2-10 Users

          $300

          Annually per user

          $300/year Get Started

          $300 Annually per user

          View All Plans

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          explore

          Bright Health sells Medicare Advantage business to Molina
          Bright Health sells Medicare Advantage business to Molina

          BrightHealthisofficiallyleavingthehealthinsurancemarket.ThecompanyhasagreedtosellitsMedicareAdvantag

          read more
          Medicare Advantage proposed rates disappoint insurers
          Medicare Advantage proposed rates disappoint insurers

          AdobeYou’rereadingthewebversionofHealthCareInc., STAT’sweeklynewsletter followingtheflowofmoneyinmed

          read more
          The cancer drug shortage isn’t new — and neither are the solutions
          The cancer drug shortage isn’t new — and neither are the solutions

          PreparingachemotherapytreatmentatDukeCancerCenterinDurham,N.C.GerryBroome/APAyounggirl,maybe5or6year

          read more

          Robert F. Kennedy is pitching centrism on health, even on abortion

          RobertF.KennedyJr.talkswithreportersinthelobbyofTrumpTowerin2017.EvanVucci/APYou’rereadingthewebedit